Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TLR2 | O60603 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22566683 | 0.97 | GLP1R (0.39) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL20370986 | 0.94 | GLP1R (0.42) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL20375516 | 0.91 | GLP1R (0.41) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL24479569 | 0.90 | GLP1R (0.43) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL18715377 | 0.90 | GLP1R (0.43) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL18715404 | 0.90 | GLP1R (0.43) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL23714533 | 0.90 | GLP1R (0.40) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL20800932 | 0.89 | GLP1R (0.43) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL23714560 | 0.89 | GLP1R (0.40) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL23869978 | 0.89 | GLP1R (0.43) | GLP1RPOLBPLGPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355651-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230323350-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-10-12 | — | — | US | disclosed |
| US-11590156-B2 | RNAi agents for hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11517584-B2 | RNAi agents for Hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2022-12-06 | — | — | US | disclosed |
| US-11492624-B2 | RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1 | Arrowheads Pharmaceuticals, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11214801-B2 | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | Arrowhead Pharmaceuticals, Inc. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210403908-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS D VIRUS INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2021-12-30 | — | — | US | disclosed |
| US-20210395745-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2021-12-23 | — | — | US | disclosed |
| US-11203756-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210285000-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | Janssen Pharmaceuticals, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20200283777-A1 | RNAi Agents And Compositions for Inhibiting Expression of Asiaglycoprotein Receptor 1 | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2020-09-10 | — | — | US | disclosed |
| US-20200208149-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2020-07-02 | — | — | US | disclosed |
| US-10597657-B2 | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | Arrowhead Pharmaceuticals, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190382763-A1 | Compositions and Methods for Inhibition of Factor XII Gene Expression | Arrowhead Pharmaceuticals, Inc. | 2019-12-19 | — | — | US | disclosed |
| US-10450565-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190292547-A1 | RNAi Agents for Hepatitis B Virus Infection | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-09-26 | — | — | US | disclosed |
| US-20190255091-A1 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190078088-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-03-14 | — | — | US | disclosed |
| US-20190078089-A1 | RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-03-14 | — | — | US | disclosed |
| US-20180195069-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (20 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200208149-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885POLB 2045/4885PLG 1187/4885 |
| US-11590156-B2 | RNAi agents for hepatitis B virus infection | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885POLB 1022/4885PLG 3145/4885 |
| US-20230355651-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885POLB 1022/4885PLG 3145/4885 |
| US-10450565-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885POLB 2045/4885PLG 1187/4885 |
| US-11203756-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885POLB 2045/4885PLG 1187/4885 |
| US-20180195069-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885POLB 2045/4885PLG 1187/4885 |
| US-11492624-B2 | RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1 | ASGR1, LDLR, SCARB1 | GLP1R 217/4885POLB 3926/4885PLG 2531/4885 |
| US-11214801-B2 | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | APOB, LDLR, APOL1 | GLP1R 2229/4885POLB 2356/4885PLG 1640/4885 |
| US-20190078088-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | APOB, LDLR, APOL1 | GLP1R 2229/4885POLB 2356/4885PLG 1640/4885 |
| US-10597657-B2 | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | APOB, LDLR, APOL1 | GLP1R 2229/4885POLB 2356/4885PLG 1640/4885 |
| US-20210285000-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | HAVCR2, EIF2AK2, IFNAR1 | GLP1R 4338/4885POLB 664/4885PLG 4435/4885 |
| US-20210395745-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, NR1H4 | GLP1R 3941/4885POLB 1616/4885PLG 3371/4885 |
| US-20210403908-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS D VIRUS INFECTION | HAVCR2, EIF2AK2, HDGF | GLP1R 4794/4885POLB 614/4885PLG 2110/4885 |
| US-20200283777-A1 | RNAi Agents And Compositions for Inhibiting Expression of Asiaglycoprotein Receptor 1 | ASGR1, LDLR, SCARB1 | GLP1R 405/4885POLB 4166/4885PLG 2145/4885 |
| US-20190078089-A1 | RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use | TEK, PLIN3, PNLIP | GLP1R 459/4885POLB 3864/4885PLG 1011/4885 |
| US-20230323350-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | APOB, LDLR, APOL1 | GLP1R 2229/4885POLB 2356/4885PLG 1640/4885 |
| US-11517584-B2 | RNAi agents for Hepatitis B virus infection | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885POLB 1022/4885PLG 3145/4885 |
| US-20190292547-A1 | RNAi Agents for Hepatitis B Virus Infection | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885POLB 1022/4885PLG 3145/4885 |
| US-20190382763-A1 | Compositions and Methods for Inhibition of Factor XII Gene Expression | F12, F13A1, F13B | GLP1R 4018/4885POLB 3236/4885PLG 117/4885 |
| US-20190255091-A1 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885POLB 1022/4885PLG 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.